Background: In clinical practice, several strategies and pharmacological options are available to treat neuropsychiatric symptoms of Huntington disease (HD). However, there is currently insufficient data for evidence-based guidelines on the management of these common symptoms.
Objective: We aimed to develop expert-based recommendations regarding the management of agitation, anxiety, apathy, psychosis, and sleep disorders.
Methods: Guideline development was based on a modified Institute of Medicine guideline process that accounted for a lack of evidence base. An international committee of 11 multidisciplinary experts proposed a series of statements regarding the description and management of each symptom. Statement assessment and validation was performed using a web-based survey tool and 84 international HD experts (neurologists and psychiatrists) who assessed the statements and indicated their level of agreement.
Results: High-level agreement (≥85% experts strongly agreed or agreed) was reached for 107 of the 110 statements that have been incorporated into the expert-based clinical recommendations presented herein.
Conclusions: Clinical statements to guide the routine management of agitation, anxiety, apathy, psychosis, and sleep disorders in HD have been developed. Although not specifically tested in the HD population, clinical experience has shown that most of the neuropsychiatric symptoms discussed, when considered in isolation are treatable using pharmacologic and non-pharmacologic strategies developed for use in other populations. However, the management of neuropsychiatric symptoms in HD can be complex because neuropsychiatric symptoms often co-exist and treatment decisions should be adapted to cover all symptoms while limiting polypharmacy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294590 | PMC |
| http://dx.doi.org/10.3233/JHD-180293 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Psychometric evaluation of the psychosis screening questionnaire in South Africa with attention to overlap between symptoms and normative cultural beliefs.
World Cult Psychiatry Res Rev
January 2023
Columbia University Vagelos College of Physicians and Surgeons, Department of Psychiatry, New York, USA.
We evaluated the 5-item Psychosis Screening Questionnaire (PSQ) against a diagnostic gold standard in South Africa. 1885 adults at primary and tertiary health facilities were screened with the PSQ and diagnosed using the Mini International Neuropsychiatric Interview-V. Minor adaptations were required of both instruments to distinguish between psychiatric symptoms and normative cultural beliefs.
View Article and Find Full Text PDFPsychiatric Symptoms Among Adolescents and Young Adults With or Without the Huntingtin Gene Expansion.
J Neuropsychiatry Clin Neurosci
January 2025
Departments of Neurology (Watson, Pfalzer, Snow, Diehl, McDonell, Claassen) and Pathology, Microbiology, and Immunology (Vnencak-Jones), Vanderbilt University Medical Center, Nashville; Department of Psychology and Human Development (Ciriegio, Snow, Compas), Vanderbilt University, Nashville; Department of Psychiatry, University of Iowa, Iowa City (Long).
Objective: Using a multi-informant approach, the authors assessed the psychiatric symptoms of adolescents and young adults with or without the huntingtin gene expansion and examined the association of psychiatric symptoms with cumulative disease exposure, a measure taking into account age and genetic data.
Methods: The sample included 110 participants with (N=71) or without (N=39) the gene expansion, along with 85 family members who provided collateral reports. Saliva samples were used for genetic testing.
Changes in Neuropsychiatric Symptoms Among COVID-19-Convalescent Patients During Hospitalization at a Tertiary Care Center.
J Neuropsychiatry Clin Neurosci
January 2025
Department of Clinical Research, National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City (Coronel Manzo, Flores Ramos); Departments of Neurology (Amscheridam Herrera) and Internal Medicine (Zapata Arenas), General Hospital of Mexico, Mexico City; Third Medical Department and University Cancer Center, Johannes Gutenberg University, Mainz, Germany (de Jesús Naveja); Department of Psychiatry, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City (Castillejos); Faculty of Medicine, Psychiatry, and Mental Health, National Autonomous University of Mexico, Mexico City (López Sepúlveda).
Objective: The investigators compared neuropsychiatric symptoms among COVID-19 patients at hospital admission and at discharge.
Methods: Clinical data on neuropsychiatric syndromes were prospectively collected from 103 COVID-19 patients at admission and immediately before discharge. Clinical evaluations and serum biomarkers were analyzed to assess their relationship with neuropsychiatric symptoms and patient survival.
Neuroactive steroid biosynthesis during pregnancy predicts future postpartum depression: a role for the 3α and/or 3β-HSD neurosteroidogenic enzymes?
Neuropsychopharmacology
January 2025
Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, USA.
Postpartum depression (PPD) affects ~10-15% of childbearing individuals, with deleterious consequences for two generations. Recent research has explored the biological mechanisms of PPD, particularly neuroactive steroids (NAS). We sought here to investigate associations between NAS levels and ratios during pregnancy and the subsequent development of depressive symptoms with postpartum onset.
View Article and Find Full Text PDFSynaptic vulnerability to amyloid-β and tau pathologies differentially disrupts emotional and memory neural circuits.
Mol Psychiatry
January 2025
Institut de Neurociències, Department de Bioquímica i Biologia Molecular, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.
Alzheimer's disease (AD) is characterized by memory loss and neuropsychiatric symptoms associated with cerebral amyloid-β (Aβ) and tau pathologies, but whether and how these factors differentially disrupt neural circuits remains unclear. Here, we investigated the vulnerability of memory and emotional circuits to Aβ and tau pathologies in mice expressing mutant human amyloid precursor protein (APP), Tau or both APP/Tau in excitatory neurons. APP/Tau mice develop age- and sex-dependent Aβ and phosphorylated tau pathologies, the latter exacerbated at early stages, in vulnerable brain regions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!